GL Sciences Inc. Logo

GL Sciences Inc.

7705.T

(3.5)
Stock Price

2.759,00 JPY

6.42% ROA

10.84% ROE

7.95x PER

Market Cap.

28.306.512.300,00 JPY

19.54% DER

2.54% Yield

9.29% NPM

GL Sciences Inc. Stock Analysis

GL Sciences Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

GL Sciences Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.9x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (19%), which means it has a small amount of debt compared to the ownership it holds

3 Net Profit Growth

The net profit of this company has steadily increased over the last five years, showcasing a favorable financial performance and making it an enticing option for investors seeking growth potential.

4 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 ROE

ROE in an average range (13.18%) suggests satisfactory profitability and decent utilization of shareholders' equity.

6 ROA

The stock's ROA (8.69%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

7 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

8 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

9 Dividend

Investors can take comfort in the fact that the company has consistently distributed dividends over the past three years, demonstrating a commitment to rewarding shareholders.

10 Buffet Intrinsic Value

The company's stock seems undervalued (30.857) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

GL Sciences Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

GL Sciences Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

GL Sciences Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

GL Sciences Inc. Revenue
Year Revenue Growth
2007 18.537.390.000
2008 16.323.794.000 -13.56%
2009 15.679.337.000 -4.11%
2010 16.217.351.000 3.32%
2011 16.509.328.000 1.77%
2012 16.740.279.000 1.38%
2013 18.579.122.000 9.9%
2014 18.144.767.000 -2.39%
2015 18.499.830.000 1.92%
2016 20.582.912.000 10.12%
2017 22.938.907.000 10.27%
2018 24.800.749.000 7.51%
2019 25.530.477.000 2.86%
2020 29.217.283.000 12.62%
2021 33.119.805.000 11.78%
2022 38.679.841.000 14.37%
2023 35.815.092.000 -8%
2023 37.148.173.000 3.59%
2024 37.442.080.000 0.78%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

GL Sciences Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2007 655.985.000
2008 644.647.000 -1.76%
2009 656.881.000 1.86%
2010 640.280.000 -2.59%
2011 644.978.000 0.73%
2012 703.115.000 8.27%
2013 905.079.000 22.31%
2014 885.808.000 -2.18%
2015 777.935.000 -13.87%
2016 830.279.000 6.3%
2017 807.452.000 -2.83%
2018 757.082.000 -6.65%
2019 768.208.000 1.45%
2020 753.660.000 -1.93%
2021 783.664.000 3.83%
2022 840.074.000 6.71%
2023 0 0%
2023 984.646.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

GL Sciences Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2007 199.065.000
2008 264.449.000 24.72%
2009 377.671.000 29.98%
2010 344.546.000 -9.61%
2011 314.219.000 -9.65%
2012 212.606.000 -47.79%
2013 212.746.000 0.07%
2014 223.014.000 4.6%
2015 229.204.000 2.7%
2016 249.951.000 8.3%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

GL Sciences Inc. EBITDA
Year EBITDA Growth
2007 3.918.516.000
2008 3.451.318.000 -13.54%
2009 3.235.881.000 -6.66%
2010 3.712.500.000 12.84%
2011 3.816.947.000 2.74%
2012 4.254.311.000 10.28%
2013 4.837.704.000 12.06%
2014 4.270.635.000 -13.28%
2015 4.436.240.000 3.73%
2016 5.437.274.000 18.41%
2017 3.377.512.000 -60.98%
2018 4.063.897.000 16.89%
2019 3.944.270.000 -3.03%
2020 5.101.831.000 22.69%
2021 6.217.119.000 17.94%
2022 8.091.886.000 23.17%
2023 6.105.624.000 -32.53%
2023 7.443.115.000 17.97%
2024 7.567.688.000 1.65%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

GL Sciences Inc. Gross Profit
Year Gross Profit Growth
2007 5.592.101.000
2008 4.999.222.000 -11.86%
2009 4.874.668.000 -2.56%
2010 5.363.237.000 9.11%
2011 5.475.700.000 2.05%
2012 5.918.015.000 7.47%
2013 6.701.087.000 11.69%
2014 6.045.743.000 -10.84%
2015 6.088.491.000 0.7%
2016 7.209.579.000 15.55%
2017 8.154.176.000 11.58%
2018 8.755.776.000 6.87%
2019 8.514.488.000 -2.83%
2020 9.780.074.000 12.94%
2021 11.230.449.000 12.91%
2022 13.409.894.000 16.25%
2023 13.077.272.000 -2.54%
2023 13.487.780.000 3.04%
2024 14.176.744.000 4.86%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

GL Sciences Inc. Net Profit
Year Net Profit Growth
2007 572.087.000
2008 -152.304.000 475.62%
2009 190.649.000 179.89%
2010 371.662.000 48.7%
2011 609.806.000 39.05%
2012 525.500.000 -16.04%
2013 777.378.000 32.4%
2014 632.728.000 -22.86%
2015 773.864.000 18.24%
2016 1.318.581.000 41.31%
2017 1.747.030.000 24.52%
2018 2.006.222.000 12.92%
2019 1.633.485.000 -22.82%
2020 2.257.216.000 27.63%
2021 2.795.295.000 19.25%
2022 3.499.060.000 20.11%
2023 3.294.760.000 -6.2%
2023 3.430.655.000 3.96%
2024 3.209.656.000 -6.89%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

GL Sciences Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2007 51
2008 -14 492.31%
2009 19 172.22%
2010 36 50%
2011 59 38.98%
2012 51 -15.69%
2013 76 32%
2014 62 -22.95%
2015 75 18.67%
2016 129 41.41%
2017 170 24.71%
2018 196 12.82%
2019 159 -22.64%
2020 220 27.73%
2021 272 19.12%
2022 341 20.23%
2023 0 0%
2023 334 100%
2024 313 -7.05%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

GL Sciences Inc. Free Cashflow
Year Free Cashflow Growth
2007 97.874.000
2008 1.326.700.000 92.62%
2009 594.624.000 -123.12%
2010 461.179.000 -28.94%
2011 1.029.854.000 55.22%
2012 1.263.170.000 18.47%
2013 -154.111.000 919.65%
2014 665.606.000 123.15%
2015 601.855.000 -10.59%
2016 960.137.000 37.32%
2017 -248.588.000 486.24%
2018 79.788.000 411.56%
2019 844.603.000 90.55%
2020 -600.873.000 240.56%
2021 913.136.000 165.8%
2022 -1.172.210.000 177.9%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

GL Sciences Inc. Operating Cashflow
Year Operating Cashflow Growth
2007 1.178.833.000
2008 1.920.798.000 38.63%
2009 1.025.906.000 -87.23%
2010 832.953.000 -23.16%
2011 1.474.386.000 43.51%
2012 1.808.938.000 18.49%
2013 706.867.000 -155.91%
2014 1.351.645.000 47.7%
2015 1.341.794.000 -0.73%
2016 1.739.128.000 22.85%
2017 1.749.965.000 0.62%
2018 2.088.864.000 16.22%
2019 2.233.712.000 6.48%
2020 2.743.745.000 18.59%
2021 3.690.928.000 25.66%
2022 1.986.658.000 -85.79%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

GL Sciences Inc. Capital Expenditure
Year Capital Expenditure Growth
2007 1.080.959.000
2008 594.098.000 -81.95%
2009 431.282.000 -37.75%
2010 371.774.000 -16.01%
2011 444.532.000 16.37%
2012 545.768.000 18.55%
2013 860.978.000 36.61%
2014 686.039.000 -25.5%
2015 739.939.000 7.28%
2016 778.991.000 5.01%
2017 1.998.553.000 61.02%
2018 2.009.076.000 0.52%
2019 1.389.109.000 -44.63%
2020 3.344.618.000 58.47%
2021 2.777.792.000 -20.41%
2022 3.158.868.000 12.06%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

GL Sciences Inc. Equity
Year Equity Growth
2007 15.727.667.000
2008 14.290.471.000 -10.06%
2009 14.271.060.000 -0.14%
2010 14.414.364.000 0.99%
2011 15.042.447.000 4.18%
2012 15.862.183.000 5.17%
2013 17.206.590.000 7.81%
2014 18.392.481.000 6.45%
2015 18.280.882.000 -0.61%
2016 19.577.378.000 6.62%
2017 21.690.523.000 9.74%
2018 23.489.641.000 7.66%
2019 24.742.703.000 5.06%
2020 27.756.414.000 10.86%
2021 31.529.602.000 11.97%
2022 35.578.381.000 11.38%
2023 40.209.053.000 11.52%
2023 37.368.972.000 -7.6%
2024 40.955.137.000 8.76%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

GL Sciences Inc. Assets
Year Assets Growth
2007 23.389.393.000
2008 21.421.990.000 -9.18%
2009 22.040.686.000 2.81%
2010 21.994.891.000 -0.21%
2011 22.888.707.000 3.91%
2012 22.841.903.000 -0.2%
2013 25.248.177.000 9.53%
2014 25.135.402.000 -0.45%
2015 24.417.412.000 -2.94%
2016 26.435.095.000 7.63%
2017 29.609.755.000 10.72%
2018 32.080.006.000 7.7%
2019 33.091.409.000 3.06%
2020 38.683.254.000 14.46%
2021 42.975.215.000 9.99%
2022 51.011.629.000 15.75%
2023 55.567.561.000 8.2%
2023 52.842.528.000 -5.16%
2024 55.461.855.000 4.72%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

GL Sciences Inc. Liabilities
Year Liabilities Growth
2007 7.661.726.000
2008 7.131.519.000 -7.43%
2009 7.769.626.000 8.21%
2010 7.580.527.000 -2.49%
2011 7.846.260.000 3.39%
2012 6.979.720.000 -12.42%
2013 8.041.587.000 13.2%
2014 6.742.921.000 -19.26%
2015 6.136.530.000 -9.88%
2016 6.857.717.000 10.52%
2017 7.919.230.000 13.4%
2018 8.590.365.000 7.81%
2019 8.348.706.000 -2.89%
2020 10.926.840.000 23.59%
2021 11.445.613.000 4.53%
2022 15.433.248.000 25.84%
2023 15.358.505.000 -0.49%
2023 15.473.556.000 0.74%
2024 14.506.715.000 -6.66%

GL Sciences Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
3735.68
Net Income per Share
347.03
Price to Earning Ratio
7.95x
Price To Sales Ratio
0.74x
POCF Ratio
11.24
PFCF Ratio
11.24
Price to Book Ratio
0.83
EV to Sales
0.72
EV Over EBITDA
3.69
EV to Operating CashFlow
11.02
EV to FreeCashFlow
11.02
Earnings Yield
0.13
FreeCashFlow Yield
0.09
Market Cap
28,31 Bil.
Enterprise Value
27,75 Bil.
Graham Number
5100.08
Graham NetNet
797.61

Income Statement Metrics

Net Income per Share
347.03
Income Quality
0.73
ROE
0.11
Return On Assets
0.06
Return On Capital Employed
0.13
Net Income per EBT
0.55
EBT Per Ebit
1.06
Ebit per Revenue
0.16
Effective Tax Rate
0.3

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0.02
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.37
Operating Profit Margin
0.16
Pretax Profit Margin
0.17
Net Profit Margin
0.09

Dividends

Dividend Yield
0.03
Dividend Yield %
2.54
Payout Ratio
0
Dividend Per Share
70

Operating Metrics

Operating Cashflow per Share
245.52
Free CashFlow per Share
245.52
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.1
Return on Tangible Assets
0.06
Days Sales Outstanding
111.67
Days Payables Outstanding
55.19
Days of Inventory on Hand
200.43
Receivables Turnover
3.27
Payables Turnover
6.61
Inventory Turnover
1.82
Capex per Share
0

Balance Sheet

Cash per Share
705,00
Book Value per Share
3.991,84
Tangible Book Value per Share
3991.84
Shareholders Equity per Share
3331.21
Interest Debt per Share
656.39
Debt to Equity
0.2
Debt to Assets
0.12
Net Debt to EBITDA
-0.07
Current Ratio
3.4
Tangible Asset Value
40,96 Bil.
Net Current Asset Value
18,34 Bil.
Invested Capital
40349089999
Working Capital
23,18 Bil.
Intangibles to Total Assets
0
Average Receivables
12,24 Bil.
Average Payables
3,82 Bil.
Average Inventory
12886959500
Debt to Market Cap
0.24

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

GL Sciences Inc. Dividends
Year Dividends Growth
2005 20
2006 15 -33.33%
2007 45 66.67%
2008 45 0%
2010 30 -50%
2011 30 0%
2012 30 0%
2013 30 0%
2014 32 6.25%
2015 34 5.88%
2016 18 -88.89%
2017 5 -260%
2018 30 83.33%
2019 10 -200%
2020 30 66.67%
2021 5 -500%
2022 5 0%
2023 5 0%
2024 70 92.86%

GL Sciences Inc. Profile

About GL Sciences Inc.

GL Sciences Inc. provides gas/liquid chromatography equipment, pretreatment equipment, components, fillers, analytical columns, solid phase, and peripheral equipment in Japan and internationally. The company offers sample preparation products, including solid phase extraction columns and accessories, vials, syringes, disposable filters, certified reference materials, cells, and gas sampling, as well as life sciences/bio and tubing products. It also provides liquid chromatography products, such as LC/MS columns and accessories; gas chromatography comprising GC/MS capillary columns and accessories, GC packed columns and absorbents, GC packed columns accessories, and GC instruments, as well as technical support services; and gastec detector tubes. In addition, the company offers quartz tools for use in semiconductor production; analytical instrumentation for gas chromatography systems; and LC related products, such as valves, degassers, pumps, and related products, as well as engages in the automated recognition business. It serves environmental and water, food and beverage, cosmetics, life science, metal and mining, energy, petrochemical and general chemistry, and automotive and interior material industries. The company was formerly known as gas Chromatography Industrial Co., Ltd. and changed its name to GL Sciences Inc. in October 1990. GL Sciences Inc. was founded in 1968 and is headquartered in Tokyo, Japan.

CEO
Mr. Yoshihiro Nagami
Employee
1.091
Address
Shinjuku Square Tower
Tokyo, 163-1130

GL Sciences Inc. Executives & BODs

GL Sciences Inc. Executives & BODs
# Name Age
1 Mr. Toshio Kurokawa
GM of Sales Headquarters & Director
70
2 Mr. Osamu Serizawa
GM of Administration Headquarters & Director
70
3 Mr. Yoshihiro Nagami
Chair, President & Chief Executive Officer
70

GL Sciences Inc. Competitors